• Policy
• Orphan drug Ilaris receives conditional pass for reimb again
• by Lee, Hye-Kyung Apr 5, 2024 05:43am

• Policy
• HIRA in final stages of preparing expense report survey
• by Lee, Tak-Sun Apr 5, 2024 05:43am

• Policy
• Trajenta generics enter reimbursement pricing…
• by Lee, Tak-Sun Apr 5, 2024 05:43am

• Policy
• Eye drops late to submit test results pass reivew
• by Lee, Hye-Kyung Apr 4, 2024 05:59am

• Policy
• K-CAB is in talks to extend refund-type PVA
• by Lee, Tak-Sun Apr 4, 2024 05:59am

• Policy
• Novartis’ 'Ilaris' will be reconsidered for the DREC review
• by Lee, Tak-Sun Apr 3, 2024 05:50am

• Policy
• 3 more successful Zolgensma treatment cases reported…
• by Lee, Tak-Sun Apr 2, 2024 05:54am

• Policy
• Oppo parties also promise 'drug price system reform'
• by Lee, Jeong-Hwan Apr 2, 2024 05:54am

• Policy
• Price reduction dilemma for 'Forxiga' set for withdrawal
• by Lee, Tak-Sun Apr 2, 2024 05:53am

• Policy
• K-drugs’ approval in the Philippines to be expedited
• by Lee, Tak-Sun Apr 1, 2024 05:29am